\n<\/p>\n
IMU Biosciences Raises Over $53 Million in Series A Funding<\/strong><\/p>\n IMU Biosciences has successfully raised more than $53 million (\u00a340 million) in a Series A funding round that saw strong interest from investors. This round was co-led by IQ Capital and Molten Ventures.<\/p>\n The company is making strides in understanding the immune system, aiming to change the way diseases are diagnosed and treated. By analyzing a simple blood sample, IMU can gather data on over 100 million aspects of the immune system, creating a comprehensive overview of a person\u2019s immune health.<\/p>\n With this extensive data, IMU is working to establish a universal standard for immune profiling. This will help in discovering new immune responses, tracking disease progression, and tailoring treatment plans to individual patients.<\/p>\n The recent funding round was also backed by the British Business Bank, Meltwind, and other existing investors. The money raised will be used to expand the company’s operations and develop its clinical platform and infrastructure.<\/p>\n Moreover, the investment will further IMU\u2019s clinical programs, including those focused on stem cell and solid organ transplants, along with MANIFEST, a UK research alliance exploring how patients respond to cancer immunotherapies.<\/p>\n John Baker, CEO of IMU Biosciences, emphasized the need for better understanding of the immune system, saying, \u201cEven though the immune system plays a crucial role in our health, it’s still not fully understood due to the limitations of existing tools.\u201d<\/p>\n With the largest global dataset on the immune system and innovative technology, IMU is in a powerful position to drive new discoveries, develop effective treatments, and support healthcare professionals, ultimately aiming to improve patient outcomes in various health conditions.<\/p>\n\n","protected":false},"excerpt":{"rendered":" IMU Biosciences Raises Over $53 Million in Series A Funding IMU Biosciences has successfully raised more than $53 million (\u00a340 million) in a Series A funding round that saw strong interest from investors. This round was co-led by IQ Capital and Molten Ventures. The company is making strides in understanding the immune system, aiming to<\/p>\n","protected":false},"author":1,"featured_media":33479,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[34],"tags":[43986,43987],"class_list":["post-33478","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-biotech","tag-imu-biosciences"],"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/33478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=33478"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/33478\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/33479"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=33478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=33478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=33478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}